Massimo Puoti

Professore Straordinario

University of Milano-Bicocca

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Massimo Puoti is a Professore Straordinario at Università degli Studi di Milano-Bicocca, Italy. His research areas include hepatitis C management, COVID-19 hospitalization prediction, and the treatment of HIV and related infections. He has contributed significantly to the field with recent publications on diagnostic accuracy for invasive fungal infections and treatment guidelines for hepatitis C and HIV.

Articles (11)

Year:

2025

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Alessio Aghemo

ITALY

View details

Giacomo Urbinati

University of Bologna

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Massimo Puoti

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

From Guidelines to Real‐Time Conversation: Expert‐Validated Retrieval‐Augmented and Fine‐Tuned GPT‐4 for Hepatitis C Management

Algorithm for Individual Prediction of COVID-19–Related Hospitalization Based on Symptoms: Development and Implementation Study

Reply to: Epidemiological evidence for an association between higher influenza vaccine uptake in the elderly and lower COVID‐19 deaths in Italy

Quantification of 1,3‐β‐ d ‐glucan by Wako β‐glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study

Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)

EASL recommendations on treatment of hepatitis C: Final update of the series☆

Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel.

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection

Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients

Collaborators (2)

Alessio Aghemo

Giacomo Urbinati

Make your next move.